Copyright © 1996, 1997, 2001 by Galen Daryl Knight and VitaleTherapeutics, Inc.

Effective Treatments

A long-term follow-up of results reported in Cancer Research demonstrates that the majority of weanling mice inoculated with uniformly fatal syngeneic melanoma and, after one month, treated with only four semi-monthly doses of vitalethine or its sulfenate-linked benzyl derivative survived longer than their reported virgin life-span of about 78 weeks. (In contrast, survival for five years is generally considered to be effective treatment of human cancer, the mouse equivalent of only about 5 weeks.) Efforts are under way to optimize these regimens and to determine if giving booster regimens every 10-20 weeks, similar to boosters given for tetanus vaccinations in humans, might prolong the up to 90% initial therapeutic benefit.

Similarly, in contrast to a mortality of at least 75% in mice bearing a different tumor, NS-1 myeloma, all mice inoculated with myeloma and treated with the benzyl derivative of vitalethine (100 pg/kg) exhibited long-term survival.

These rather good, lifetime responses in mice were obtained even though the regimens used have not yet been optimized. In addition to these carefully controlled studies in laboratory animals, desirable responses have also been obtained in the outpatient treatments of three out of four dogs and two horses (all suffering from spontaneous recurrent melanoma) using vitalethine or its benzyl derivative, three of which are still being monitored.


Home Overview People Journal Nutrition
WWW Links Outline e-mail us